Video
27 Oct 2022

CDMO: Health is a Joint Project

Watch Video

Indena’s view and technology expansion to support partners’ developments.

Supported by more than 100 year experience, Indena has been involved ever since in the CDMO activities on behalf of its partners, even before CDMO was so named. Starting from the extraction, chromatographic purification and isolation of natural derivatives, a core expertise of the company since its foundation, a significant technological expansion has been carried out over the years, thus now mastering fermentation (including toxic compounds), synthesis of potent and highly potent APIs and spray drying of difficult molecules.

Several technological solutions will be presented, highlighting cases where a combination of different techniques available have been instrumental to successful product development.

Did you enjoy this session? If so, you might like to visit our Connect to Frankfurt platform, where you can browse our collection of 30+ on-demand webinars and learn about our upcoming CPHI Frankfurt event, taking place 1-3 November in Frankfurt, Germany.

Bringing together the global supply chain under one roof, CPHI Frankfurt puts you at the heart of pharma. Can’t attend in person? You can access many of the event offerings online! Browse our exhibitor list, arrange meetings, view on-site content and network – all from home.

Content provided by our supplier

Indena S.P.A

  • IT
  • 2015
    On CPHI since
  • 5
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO
Manufacturer/Innovator
Pharmaceutical company
Primary activities
API Producer
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Nutraceuticals
View company profile

Other Content from Indena S.P.A (3)

  • News Indena: The next generation CDMO

    28 Sep 2023
  • From the Rainforest to the Clinic. Turning a High-Potency Rare Natural Product Into an Anticancer API

    Video From the Rainforest to the Clinic. Turning a High-Potency Rare Natural Product Into an Anticancer API

    Natural products can be characterized by complex structure, limited availability, and exceptional potency, whose combination makes it challenging their development as API. Success requires integration of expertise in different areas, including the construction of a sustainable supply chain for the starting biomass, the capacity to manipulate high-potency products in a GMP environment, and the versatility to strategically complement isolation with semi-synthesis, total synthesis and biotechnology. In this context, mutual thrust between the service provider company and the drug candidate owner is critical, and the successful development of the anticancer drug tigilanol tiglate will give the opportunity to address these issues.
    2024-10-24
  • CDMO services

    Whitepaper CDMO services

    We have a unique expertise in developing and manufacturing HPAPIs. The company is equipped with kilolabs (for clinical and small commercial batches) and large industrial suite for HPAPIs with an OEL>20 ng/m3.